The first manuscript discussing the quantitation of OACDs in CSF for monitoring their efficacy regarding the treatment of the CNS metastases of NSCLC was published on the epidermal growth factor receptor inhibitor gefitinib (Iressa®). Here, EGFR is linked to non-small cell lung carcinoma.